CloudCath

Focus: CloudCath is an early-stage medical device company developing remote catheter monitoring platforms for nephrology applications, specifically targeting peritoneal dialysis-related complications. Founded in 2022 and based in San Francisco, the company is pre-revenue and operating at a very early stage.

Nephrology

Profile data last refreshed 6h ago · AI intelligence enriched 2w ago

Open Jobs

About CloudCath

AI assessmentNot Hiring

No open roles listed right now. Follow CloudCath to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CloudCath System

End Stage Renal Disease

N/A

Clinical Trials (1)

NCT05285436A Prospective Clinical Study to Assess the Clinical Utility of Turbidity in Patients Using In-Home Peritoneal Dialysis

N/A

Help build intelligence for CloudCath

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build core functions at a founded medical device startup addressing unmet needs in nephrology—a specialty with limited innovation
Ground-floor equity upside with a focused, single-indication pipeline reduces organizational complexity early in career
Emerging market in remote monitoring for dialysis creates adjacent commercial runway if clinical validation succeeds

Watch Out For

Zero current job openings and no publicly available hiring activity signal minimal near-term growth or runway uncertainty
Pre-revenue stage with undisclosed funding means cash runway and Series A timeline are unknown; career stability is unproven
No published data, clinical trial readouts, or recent news in public record; minimal signal on product-market fit or clinical traction

Generated by Claude from CloudCath's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CloudCath Monitoring System

Peritoneal Dialysis-associated Peritonitis

N/A

Clinical Trials (1)

NCT04515498A Prospective Clinical Study of the CloudCath System During In-home Peritoneal Dialysis

N/A

Spectral characteristics assessment

Urinary Tract Infections

N/A

Clinical Trials (1)

NCT04950582In Vitro Analysis of Human Urine With the CloudCath Device

N/A

Effluent dialysate

Peritoneal Dialysis-associated Peritonitis

N/A

Clinical Trials (1)

NCT05300191In Vitro Analysis of Effluent Dialysate Solution From Patients on Peritoneal Dialysis, With the CloudCath Device

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2022

Portfolio: 4 clinical trials

Top TAs: Nephrology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Nephrology

3 pipeline

Marketed

Pipeline